Similar articles for PMID: 29547706

Year	Number of Results
2011	1
2013	2
2014	5
2015	4
2016	18
2017	27
2018	28
2019	28
2020	35
2021	73
2022	52
2023	22
2024	0

1

Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.

Lim S, Eckel RH, Koh KK. Lim S, et al. Atherosclerosis. 2018 May;272:33-40. doi: 10.1016/j.atherosclerosis.2018.03.013. Epub 2018 Mar 8. Atherosclerosis. 2018. PMID: 29547706 Review.

2

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.

Scheen AJ. Scheen AJ. Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588. Circ Res. 2018. PMID: 29748368 Free PMC article. Review.

3

Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.

Eleftheriadou I, Grigoropoulou P, Liberopoulos E, Liatis S, Kokkinos A, Tentolouris N. Eleftheriadou I, et al. Curr Med Chem. 2018;25(13):1549-1566. doi: 10.2174/0929867324666170530075533. Curr Med Chem. 2018. PMID: 28554326 Review.

4

Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.

Kaul S. Kaul S. Diabetes Care. 2017 Jul;40(7):821-831. doi: 10.2337/dc17-0291. Diabetes Care. 2017. PMID: 28637887 Review.

5

Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.

Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A. Ghosh RK, et al. Int J Cardiol. 2016 Jun 1;212:29-36. doi: 10.1016/j.ijcard.2016.02.134. Epub 2016 Mar 10. Int J Cardiol. 2016. PMID: 27017118 Review.

6

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH. van Bommel EJM, et al. Clin J Am Soc Nephrol. 2017 Apr 3;12(4):700-710. doi: 10.2215/CJN.06080616. Epub 2017 Mar 2. Clin J Am Soc Nephrol. 2017. PMID: 28254770 Free PMC article. Review.

7

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.

Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. Schernthaner G, et al. Clin Ther. 2016 Jun;38(6):1288-1298. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19. Clin Ther. 2016. PMID: 27210264

8

Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.

Bonadonna RC, Borghi C, Consoli A, Volpe M. Bonadonna RC, et al. Nutr Metab Cardiovasc Dis. 2016 Sep;26(9):759-66. doi: 10.1016/j.numecd.2016.05.007. Epub 2016 May 27. Nutr Metab Cardiovasc Dis. 2016. PMID: 27373139 Free article. Review.

9

Cardiovascular Outcome Trials with Glucose-Lowering Drugs.

Thethi TK, Bilal A, Pratley RE. Thethi TK, et al. Curr Cardiol Rep. 2021 Jun 3;23(7):75. doi: 10.1007/s11886-021-01505-3. Curr Cardiol Rep. 2021. PMID: 34081215 Review.

10

Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.

Hupfeld C, Mudaliar S. Hupfeld C, et al. Diabetes Obes Metab. 2019 Aug;21(8):1780-1789. doi: 10.1111/dom.13740. Epub 2019 Apr 29. Diabetes Obes Metab. 2019. PMID: 30957945 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

267 results

Results by year